|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 81.23 USD | +3.58% |
|
+13.28% | +20.70% |
| Capitalization | 955.24Cr 808.61Cr 741.1Cr 701.9Cr 1.3TCr 87TCr 1.36TCr 8.61TCr 3.41TCr 42TCr 3.58TCr 3.51TCr 1,50000Cr | P/E ratio 2025 * |
14.4x | P/E ratio 2026 * | 10.9x |
|---|---|---|---|---|---|
| Enterprise value | 1.03TCr 871.75Cr 798.97Cr 756.71Cr 1.41TCr 93TCr 1.47TCr 9.28TCr 3.68TCr 45TCr 3.86TCr 3.78TCr 1,61700Cr | EV / Sales 2025 * |
7.39x | EV / Sales 2026 * | 5.28x |
| Free-Float |
98.92% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Halozyme Therapeutics, Inc.
| 1 day | +3.58% | ||
| 1 week | +13.28% | ||
| Current month | +13.28% | ||
| 1 month | +8.15% | ||
| 3 months | +19.04% | ||
| 6 months | +30.81% | ||
| Current year | +20.70% |
| 1 week | 71.22 |  | 81.36 |
| 1 month | 68.85 | | 81.36 |
| Current year | 67.16 | | 81.36 |
| 1 year | 47.5 | | 81.36 |
| 3 years | 29.85 | | 81.36 |
| 5 years | 29.85 | | 81.36 |
| 10 years | 6.96 | | 81.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 63 | 06/01/2014 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 43 | 02/02/2022 |
Charles Theuer
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 58 | 28/03/2013 |
Helen Torley
BRD | Director/Board Member | 63 | 06/01/2014 |
| Chairman | 62 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.58% | +13.28% | +42.26% | +57.21% | 955.24Cr | |
| -0.49% | -3.27% | -13.34% | -33.51% | 6.24TCr | |
| +1.37% | -4.07% | +13.49% | -17.10% | 801.06Cr | |
| -2.69% | -8.05% | -15.17% | +50.28% | 580.72Cr | |
| -2.42% | -2.96% | -23.45% | +108.80% | 532.17Cr | |
| -0.26% | -2.88% | +258.66% | +41.52% | 429Cr | |
| +4.62% | +7.25% | +34.51% | +35.42% | 296.16Cr | |
| -6.59% | -19.37% | +371.99% | +910.91% | 288.45Cr | |
| -0.61% | +0.28% | -18.27% | -24.90% | 286.19Cr | |
| Average | -0.39% | -0.80% | +72.30% | +125.40% | 1.16TCr | |
| Weighted average by Cap. | -0.21% | -1.93% | +16.33% | +19.50% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 139.37Cr 117.97Cr 108.12Cr 102.4Cr 190.15Cr 13TCr 198.8Cr 1.26TCr 497.44Cr 6.08TCr 522.66Cr 511.9Cr 22TCr | 176.37Cr 149.3Cr 136.84Cr 129.6Cr 240.64Cr 16TCr 251.6Cr 1.59TCr 629.53Cr 7.69TCr 661.45Cr 647.84Cr 28TCr |
| Net income | 70Cr 59Cr 54Cr 51Cr 95Cr 6.3TCr 99Cr 627.03Cr 248.23Cr 3.03TCr 260.82Cr 255.45Cr 11TCr | 89Cr 76Cr 69Cr 66Cr 121.76Cr 8.08TCr 127.3Cr 804.58Cr 318.52Cr 3.89TCr 334.67Cr 327.78Cr 14TCr |
| Net Debt | 75Cr 63Cr 58Cr 55Cr 101.76Cr 6.76TCr 106.39Cr 672.45Cr 266.21Cr 3.25TCr 279.71Cr 273.96Cr 12TCr | -23Cr -20Cr -18Cr -17Cr -32Cr -2.11TCr -33Cr -210.29Cr -83Cr -1.02TCr -87Cr -86Cr -3.66TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/26/06 | 81.23 $ | +3.58% | 22,45,820 |
| 05/26/05 | 78.42 $ | +0.63% | 24,81,882 |
| 04/26/04 | 77.93 $ | +1.90% | 26,02,672 |
| 03/26/03 | 76.48 $ | +2.73% | 37,71,363 |
| 02/26/02 | 74.45 $ | +3.82% | 20,77,373 |
Delayed Quote Nasdaq, February 07, 2026 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HALO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition